Approvals/TGA/ABRYSVO recombinant respiratory syncytial virus pre-fusion F protein 120 microgram/0.5mL bivalent vaccine powder for injection vial and diluent syringe

Approved

STANDARD

ABRYSVO recombinant respiratory syncytial virus pre-fusion F protein 120 microgram/0.5mL bivalent vaccine powder for injection vial and diluent syringe

Pfizer Australia Pty Ltd🇦🇺 Therapeutic Goods Administration

Approval Date: May 30, 2025
Approval ID: b0ad08de84aab701
Company: Pfizer Australia Pty Ltd
Type: Standard

Approval Details

Approval Id: b0ad08de84aab701
Product Name: ABRYSVO recombinant respiratory syncytial virus pre-fusion F protein 120 microgram/0.5mL bivalent vaccine powder for injection vial and diluent syringe
Artg Id: 406624
Artg Name: ABRYSVO recombinant respiratory syncytial virus pre-fusion F protein 120 microgram/0.5 mL bivalent vaccine powder for injection vial + diluent syringe
Sponsor: Pfizer Australia Pty Ltd
Company Detail Path: /organization/pfizer-australia-pty-ltd
Artg Date: 2024-03-20
Registration Type: Medicine
Therapeutic Good Type: Medicine
Licence Status: A
Licence Category: RE
Consumer Medicine Info: https://medical-cdn.nocode.com/drug_tga/649969d9aa07a417e412e9bc40012add.pdf
Product Information: https://medical-cdn.nocode.com/drug_tga/ca4e3ef5c92f16d786c994e6005a8e27.pdf

Active Ingredients

Approved

Quick Info

Agency

TGA

Country

🇦🇺

Approval Date

May 30, 2025

Approval ID

b0ad08de84aab701

Type

Standard

Back to TGA Approvals